Position in REPL
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$220,293
New position
Shares Held
19,900
first reported quarter
Ownership
0.021%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#107
of 198 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Breakwater Capital Group holds $2,533,174 across 7 Biotechnology names. REPL ranks #6 (8.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,992 | $989,486 | |
| 2 | DNLI |
Denali Therapeutics Inc.
|
15,601 | $401,257 | |
| 3 | CYTK |
Cytokinetics Inc
|
3,941 | $335,733 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,007 | $303,137 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
2,832 | $246,242 | |
| 6 | REPL |
Replimune Group, Inc.
This page
|
19,900 | $220,293 | |
| 7 | RXRX |
Recursion Pharmaceuticals, Inc.
|
10,089 | $37,026 |
All Filings in REPL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $220,293 | 19,900 | Shares | Sole | 2026-07-08 | |
| No filing history on record for this holder in this stock. | ||||||